AWM
STAB

Accel Wealth Management’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Accel Wealth Management’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-250
Closed -$1K – 976
2021
Q4 		$1K Buy
+250
New +$738 ﹤0.01% 923

Other funds holding STAB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Accel Wealth Management's STAB Position: Q1 2022 in Review

Accel Wealth Management sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2022, closing a stake of 250 shares — an estimated $1K sold.

Accel Wealth Management first reported a position in STAB in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 33 funds tracked by Wall St. Rank hold STAB as of Q1 2022.

  • Accel Wealth Management reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Accel Wealth Management sold 250 Statera Biopharma, Inc. Common Stock shares in Q1 2022, an estimated $1K.
  • Accel Wealth Management first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Accel Wealth Management's Statera Biopharma, Inc. Common Stock position peaked at $1K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2022.

Based on Accel Wealth Management's 13F filing for Q1 2022, filed 29 Apr 2022.